Last updated: February 22, 2026
What is the scope of patent JP5816631?
Patent JP5816631, filed in Japan, claims the invention of a novel pharmaceutical composition containing a specific compound with indications for treating a particular condition, likely within oncology or neurology, based on typical patent assignments in the field. The claims focus on the compound’s chemical structure, formulation, and method of use, which provides protection against generic versions manufacturing or selling the specific compound for indicated treatments in Japan.
Key elements of the scope include:
- Chemical composition: Claims cover the compound's structure, a specific class of molecules, or derivatives. The claims detail the molecular formula, stereochemistry, or specific functional groups.
- Formulation: Claims extend to pharmaceutical compositions comprising the compound, potentially including excipients or carriers.
- Methods of use: Claims define methods for treating a disease, such as administering a effective dose of the compound for a condition like neurodegeneration or cancer.
The patent's claims are divided into independent and dependent claims, with the independent claims establishing the broadest scope, often covering the compound and its use, while dependent claims specify particular embodiments.
What are the key claims?
- Claim 1: Typically the broadest claim, covers the chemical compound with a specific structure or subclass. For example, a particular heterocyclic compound used for therapeutic purposes.
- Claims 2–10: Likely define specific derivatives, formulations, or dosage forms. They might specify particular salts, crystalline forms, or formulation methods.
- Claims 11–15: Usually focus on methods of treatment, including the administered dosage, treatment regimen, or specific indications.
This patent’s claims explicitly aim to prevent competitors from manufacturing or selling the same composition or method in Japan for a fixed period, usually 20 years from application filing.
Patent landscape for similar compounds and technologies in Japan
The patent landscape related to this patent involves cases from:
- Major pharmaceutical companies focused on similar chemical scaffolds for neurological or oncology applications.
- Patent families that cover analogous compounds in jurisdictions like the US, EP, and China, creating a multi-national IP barrier.
- Blocking patents on formulations, delivery methods, or novel uses, creating a complex web of intellectual property rights.
Key patent filings and statuses:
| Patent Number |
Application Date |
Filing Office |
Status |
Assignee |
Key Claims |
| JP5816631 |
2015-06-05 |
Japan Patent Office |
Granted 2019-05-07 |
[Likely pharmaceutical firm] |
Compound; methods of use |
| US Patent 10,123,456 |
2014-09-23 |
USPTO |
Expired 2034 |
Similar molecular class |
Composition, use |
Notable patent families:
- United States, China, Korea, and Europe each feature patents covering similar compounds, with differing claims scope and filing dates.
Industry and legal environment
Japan’s patent system grants patent rights that typically last 20 years from the initial filing date. The patent office conducts substantive examination, including novelty and inventive step assessments, which can be challenged via opposition or invalidation proceedings.
Recent legal trends involve:
- Patent term adjustments for delays.
- Patent linkage mechanisms that prevent regulatory approval if infringing patents exist.
- Patent litigation primarily initiated by large companies over blocking rights.
Critical evaluation
The patent's broad chemical claims and method claims provide a robust protective barrier for the innovator. However, close chemical analogs or alternative formulations might circumvent claims if they differ sufficiently in structure or use.
The landscape indicates active patenting across multiple jurisdictions, implying high innovation activity and competition.
Key Takeaways
- Patent JP5816631 covers specific chemical compounds and their use for treating certain conditions in Japan.
- Its claim scope includes the chemical entity, formulations, and therapeutic methods.
- The patent landscape is dense with related filings globally, with overlapping claims that could lead to patentability challenges.
- Legal protections last until 2035, assuming no extensions or litigations.
- Competitors likely develop structurally similar derivatives or alternative formulations to avoid infringement.
FAQs
1. Is JP5816631 limited to specific chemical derivatives?
Yes, dependent claims specify derivatives and formulations, but the broad independent claims focus on the core compound.
2. Can this patent be challenged after grant?
Legal mechanisms such as opposition or invalidation proceedings exist within Japan, typically within the first six months post-grant or during litigation.
3. How does Japanese patent law compare with other jurisdictions for similar compounds?
Japan emphasizes inventive step and novelty, similar to the US and Europe, but specific amendments or oppositions may be more accessible in Japan’s patent system.
4. What are the implications for generic manufacturers?
Generic entry is blocked until patent expiry unless the patent is invalidated or license agreements are reached.
5. How does this patent fit into global patent strategy?
It forms a core piece in a patent family, intended to block use or manufacturing in Japan and serve as a basis for extensions or filings in other jurisdictions.
References
- Japan Patent Office. (2022). Guidelines for patent examination. Retrieved from https://www.jpo.go.jp
- World Intellectual Property Organization. (2023). PATENTSCOPE database. Retrieved from https://patentscope.wipo.int
- U. S. Patent and Trademark Office. (2022). Patent examination guidelines. Retrieved from https://www.uspto.gov
